JP6890135B2 - 腸内微生物叢を調節するための方法 - Google Patents

腸内微生物叢を調節するための方法 Download PDF

Info

Publication number
JP6890135B2
JP6890135B2 JP2018557190A JP2018557190A JP6890135B2 JP 6890135 B2 JP6890135 B2 JP 6890135B2 JP 2018557190 A JP2018557190 A JP 2018557190A JP 2018557190 A JP2018557190 A JP 2018557190A JP 6890135 B2 JP6890135 B2 JP 6890135B2
Authority
JP
Japan
Prior art keywords
defensin
fat
hbd2
defensins
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018557190A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504122A5 (enExample
JP2019504122A (ja
Inventor
ノードキルド，ピーター
ウェカンプ，ジャン
クジャルレフ，ソレン
Original Assignee
ディフェンシン セラピューティクス エーピーエス
ディフェンシン セラピューティクス エーピーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディフェンシン セラピューティクス エーピーエス, ディフェンシン セラピューティクス エーピーエス filed Critical ディフェンシン セラピューティクス エーピーエス
Publication of JP2019504122A publication Critical patent/JP2019504122A/ja
Publication of JP2019504122A5 publication Critical patent/JP2019504122A5/ja
Application granted granted Critical
Publication of JP6890135B2 publication Critical patent/JP6890135B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018557190A 2016-01-26 2017-01-26 腸内微生物叢を調節するための方法 Expired - Fee Related JP6890135B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201670041 2016-01-26
DKPA201670041 2016-01-26
DKPA201670483 2016-07-01
DKPA201670483 2016-07-01
PCT/DK2017/050017 WO2017129195A1 (en) 2016-01-26 2017-01-26 Methods for modulating intestinal microbiota

Publications (3)

Publication Number Publication Date
JP2019504122A JP2019504122A (ja) 2019-02-14
JP2019504122A5 JP2019504122A5 (enExample) 2020-12-24
JP6890135B2 true JP6890135B2 (ja) 2021-06-18

Family

ID=58056942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018557190A Expired - Fee Related JP6890135B2 (ja) 2016-01-26 2017-01-26 腸内微生物叢を調節するための方法

Country Status (14)

Country Link
US (1) US20190111107A1 (enExample)
EP (1) EP3407905B1 (enExample)
JP (1) JP6890135B2 (enExample)
KR (1) KR20180121489A (enExample)
CN (1) CN108778309A (enExample)
AU (1) AU2017212534A1 (enExample)
BR (1) BR112018015170A2 (enExample)
CA (1) CA3012711A1 (enExample)
ES (1) ES2871117T3 (enExample)
MX (1) MX2018009100A (enExample)
RU (1) RU2738265C2 (enExample)
SG (1) SG11201805954WA (enExample)
WO (1) WO2017129195A1 (enExample)
ZA (1) ZA201804515B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102465341B1 (ko) 2016-04-29 2022-11-09 디펜신 테라퓨틱스 에이피에스 간, 담관 및 췌장 장애의 치료
US12297272B2 (en) 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
DE102017219504A1 (de) 2017-11-02 2019-05-02 Bayerische Motoren Werke Aktiengesellschaft Beleuchtungsvorrichtung für ein Kraftfahrzeug
EP3706773A2 (en) * 2017-11-10 2020-09-16 Defensin Therapeutics ApS Maturation of mucosal defense and gut/lung function in the preterm infant
CA3083315A1 (en) * 2017-11-24 2019-05-31 Defensin Therapeutics Aps Prevention and treatment of graft-versus-host-disease with defensins
JP7479381B2 (ja) * 2019-01-07 2024-05-08 アエスクルス バイオ エーピーエス 治療または予防に使用するためのディフェンシン断片
CN110447763B (zh) * 2019-07-05 2023-01-20 江西农业大学 细菌在影响动物瘦肉率和/或脂肪含量中的应用
CN114072071A (zh) * 2019-07-19 2022-02-18 华盛顿大学 影响人类肠道微生物的组合物和方法
CN111202752A (zh) * 2020-02-17 2020-05-29 上海市内分泌代谢病研究所 阿克曼氏菌组合物
CN111153982B (zh) * 2020-02-17 2022-05-31 西北农林科技大学 一种反刍动物瘤胃特异抗菌肽defb1及其应用
CN111635874B (zh) * 2020-06-05 2022-03-18 江南大学 一株能够调控肠道阿克曼菌属相对丰度的脆弱拟杆菌
KR102363098B1 (ko) * 2020-06-19 2022-02-16 한국식품연구원 장내 미생물을 이용한 신질환 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 신질환 예방 또는 치료제 스크리닝 방법
KR102363092B1 (ko) * 2020-06-19 2022-02-16 한국식품연구원 장내 미생물을 이용한 비만 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 비만 예방 또는 치료제 스크리닝 방법
CN111938158B (zh) * 2020-08-18 2023-07-07 广东弘元普康医疗科技有限公司 一种防止肠道Akkermansia muciniphila菌丰度降低的组合物
CN112121152B (zh) * 2020-09-25 2021-06-22 南京大学 利司那肽在制备抗肿瘤药物中的应用
CA3229580A1 (en) * 2021-08-20 2023-02-23 Anna Nikolaevna STRELKOVA Method for producing modified adeno-associated virus capsid
KR102740789B1 (ko) * 2021-10-26 2024-12-11 가톨릭대학교 산학협력단 장내 마이크로바이옴을 이용한 천식의 중증도 및 복부비만 위험도 예측 방법
CN115125167A (zh) * 2022-06-15 2022-09-30 上海交通大学医学院附属瑞金医院 微生物组合及其用途
CN114874311A (zh) * 2022-06-20 2022-08-09 成都施桂行医药科技有限责任公司 防御肽及其制备方法和应用
CN116268203B (zh) * 2023-01-20 2024-08-20 中国农业大学 嗜黏蛋白阿克曼菌膜蛋白Amuc_1100在改善家禽蛋品质中的用途
CN120535656B (zh) * 2025-05-26 2025-12-12 中国农业大学 一种抗菌重组蛋白及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528107B2 (en) * 2005-11-30 2009-05-05 Auburn University Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins
WO2007133373A2 (en) * 2006-05-01 2007-11-22 England Robert L TNF-α VACCINE FOR TREATING DISEASE CONDITIONS MEDIATED BY PATHOLOGICAL TNF-α
WO2008115390A2 (en) * 2007-03-16 2008-09-25 The Hamner Institutes For Health Sciences Methods of using defensins to treat diabetes
US20110311601A1 (en) * 2010-06-22 2011-12-22 Michael Kleine Antimicrobial medical devices
EP2729159B1 (en) * 2011-07-08 2017-05-24 Defensin Therapeutics ApS Oral treatment of inflammatory bowel disease
WO2013026794A1 (en) * 2011-08-19 2013-02-28 Novozymes Novel immunomodulatory peptide
CN104971343B (zh) * 2015-07-13 2018-02-02 韩源平 防御素在制备治疗代谢综合征药物方面的应用

Also Published As

Publication number Publication date
SG11201805954WA (en) 2018-08-30
ES2871117T3 (es) 2021-10-28
CN108778309A (zh) 2018-11-09
MX2018009100A (es) 2019-02-28
RU2018129160A3 (enExample) 2020-05-29
RU2018129160A (ru) 2020-02-27
KR20180121489A (ko) 2018-11-07
BR112018015170A2 (pt) 2018-12-18
RU2738265C2 (ru) 2020-12-11
ZA201804515B (en) 2021-01-27
EP3407905A1 (en) 2018-12-05
EP3407905B1 (en) 2021-02-17
US20190111107A1 (en) 2019-04-18
WO2017129195A1 (en) 2017-08-03
CA3012711A1 (en) 2017-08-03
AU2017212534A1 (en) 2018-07-26
JP2019504122A (ja) 2019-02-14

Similar Documents

Publication Publication Date Title
JP6890135B2 (ja) 腸内微生物叢を調節するための方法
KR102011924B1 (ko) 인슐린 저항성에 대한 개선된 펩티드 제약
RU2635966C2 (ru) Фармацевтическая композиция для предупреждения или лечения неалкогольной жировой болезни печени
US11773150B2 (en) Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
JP2017537894A (ja) Ｇｌｐ−１ｒおよびｇｌｐ−２ｒ二重アゴニスト活性を有する組成物及びペプチド
JP2023071869A (ja) グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト
RU2740913C2 (ru) Лечение нарушений со стороны печени, желчных путей и поджелудочной железы
CN113248628B (zh) 一种乳源多肽衍生物及其在制备肥胖症防治药物、保健品和食品添加物中的应用
JP2016540741A (ja) Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
BRPI0610091B1 (pt) Análogo de peptídeo 2 tipo glucagon (glp-2), composição farmacêutica, uso de um análogo de glp-2, e, kit terapêutico
TW201410703A (zh) 艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
JP2019500369A (ja) 神経性状態および神経変性状態の治療としての長時間作用型ＧＬＰ−１ｒアゴニスト
KR20230160369A (ko) Gip 및 glp-1의 이중 수용체 작용제, 약물 조성물 및 용도
JP2002502369A (ja) 胃腸管上部の機能を強化する方法
CN119431514A (zh) 一种gcgr、gipr和glp-1r三重靶向激动作用的多肽衍生物
CN116970062B (zh) 一种超长效glp-1多肽衍生物及其制备方法和用途
HK40001163B (en) Methods for modulating intestinal microbiota
RU2779314C2 (ru) Коагонисты рецепторов глюкагона и glp-1 длительного действия

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201110

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20201110

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20201117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210427

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210524

R150 Certificate of patent or registration of utility model

Ref document number: 6890135

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees